HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• As use of robotic surgery increases, training and regulation become more rigorous
• Is the cost of robotic-assisted surgery for cancer justifiable?
• Schrödinger’s cat: PSA screening is alive and dead Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• Shared decision-making in cancer treatment ‘worth the effort’ Beth Faiman, PhD, MSN, APRN-BC, AOCN
• Radiation choice for brain metastases requires ‘transparent discussion of tradeoffs’ Andrew B. Lassman, MD; Minesh Mehta, MD; Melissa A.L. Vyfhuis, MD, PhD
• The vanishing role of whole brain radiation for limited brain metastases Paul D. Brown, MD; Ayal A. Aizer, MD, MHS
• Cabozantinib improves OS for HCC
• Apalutamide slows development of prostate cancer metastases
• Checkpoint inhibitors may have role posttransplant for aggressive B-cell lymphoma
• Cyclophosphamide combination superior for graft-versus-host disease prophylaxis
• Deep-sea creatures offer insights into efficacy of immunotherapies
• Durvalumab active in PD-L1-negative head and neck cancers
• ‘Encouraging’ results with JCAR017 for relapsed, refractory lymphoma
• Exercise reduces some chemotherapy-related side effects
• Nivolumab plus chemoradiation safe for advanced head, neck cancer
• Gene test for breast cancer recurrence not cost-effective in real world
• High costs drive underuse of brachytherapy for cervical cancer
• Increasing hydroxyurea dose reduces hospitalizations for sickle cell anemia
• Nocturia, hot flashes may explain sleep disturbance during androgen deprivation therapy
• Radioactive iodine for well-differentiated thyroid cancer increases risk for acute, chronic myeloid leukemias
• Targeted radiation reduces mortality for early-stage lung cancer
• Active surveillance for prostate cancer significantly increased over time
• FDA approves Erleada, first treatment for prostate cancer subtype
• FDA approves Trisenox plus tretinoin as first-line therapy for acute promyelocytic leukemia
• FDA grants orphan drug designation to BPM31510 for pancreatic cancer
• FDA expands clearance of ipsogen JAK2 assay for myeloproliferative neoplasms
• Beta blockers may improve response to immunotherapy in metastatic melanoma